Divalproex Sodium
Product Images NDC 53808-1027

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 53808-1027). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image For 250mg (Divalproex 250mg)

Label for Divalproex Sodium 250 mg delayed-release tablets, showing quantity of 30 tablets. The label includes manufacturing details such as manufacturer UPSHER-SMITH and lot number 313900, with an expiration date of August 7, 2014. The product is labeled RX Only and packaged by DOH Central Pharmacy, Tallahassee, FL 32304. A UPC barcode is also present.*

FDA Label Image

Chemical Structure (Divalproex 01)

Chemical structure of divalproex sodium, showing the molecular arrangement including sodium ion (Na+), carboxylate groups, and hydrocarbon chains.*

FDA Label Image

Figure 1 (Divalproex 02)

A bar graph comparing percentage values between placebo (PBO) and Divalproex Sodium (DVPX) groups in two studies. Study 1 uses the YMRS scale showing 26% for PBO and 60% for DVPX. Study 2 uses the MRS scale showing 29% for PBO and 58% for DVPX. Bars are labeled with respective percentages.*

FDA Label Image

Figure 2 (Divalproex 03)

A graph comparing the percent reduction in CPS rate for patients taking Divalproex sodium delayed-release tablets USP versus placebo. The x-axis represents the percentage of patients, and the y-axis displays the percent reduction in CPS rate, ranging from worsening to improvement. The solid line represents Divalproex sodium, and the dashed line represents placebo.*

FDA Label Image

Figure 3 (Divalproex 04)

A line graph comparing the percentage reduction in CPS rate by percentage of patients for two dosage groups labeled High Dose and Low Dose. The y-axis shows percent reduction in CPS rate from -100% to 100%, with markers for Improvement, No Change, and Worsening. The x-axis shows percentage of patients from 0 to 100%. The High Dose group is represented by a solid line, and the Low Dose by a dashed line.*

FDA Label Image

Figure 4 (Divalproex 05)

A bar chart comparing two studies showing numerical values for Placebo and Divalproex Sodium groups. Study 1 shows a higher value for Placebo than for Divalproex Sodium, and Study 2 shows a similar pattern with Placebo values higher than Divalproex Sodium values.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.